Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + cisplatin + 5-fluorouracil + leucovorin
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
A multi-agent chemotherapy regimen combining docetaxel, cisplatin, 5-fluorouracil, and leucovorin. Docetaxel is a taxane that stabilizes microtubules and inhibits depolymerization, leading to mitotic arrest. Cisplatin forms intra- and interstrand DNA crosslinks causing DNA damage and apoptosis. 5-fluorouracil is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase and incorporates into RNA and DNA, disrupting nucleic acid synthesis; leucovorin (folinic acid) enhances 5-FU’s inhibition of thymidylate synthase by stabilizing the ternary complex. The combination has been studied as induction or systemic therapy in solid tumors, notably squamous cell carcinoma of the head and neck and upper gastrointestinal malignancies including gastric and esophagogastric cancers, with dose-limiting toxicities mainly neutropenia and mucositis.
- Other names
- TPFL5TPFL-5TPFL 5opTPFLTPF plus leucovorindocetaxel cisplatin 5-fluorouracil leucovorin
02
Targets
DNATS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))Neuraminidase
Beyond the preview
Go deeper on docetaxel + cisplatin + 5-fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + cisplatin + 5-fluorouracil + leucovorin.